

asx announcement

MESOBLAST ACQUISITION OF US COMPANY APPROVED BY ANGIOBLAST STOCKHOLDERS

Melbourne, Australia, 20 October 2010: Stockholders of United States adult stem cell company Angioblast Systems Inc. voted unanimously at a special stockholders' meeting held 19 October in favour of becoming a wholly-owned subsidiary of publicly listed global regenerative medicine company, Mesoblast Limited (ASX:MSB; USOTC:MBLTY).

To increase its ownership of Angioblast from 32.8% to 100%, Mesoblast will issue approximately 94.6 million Mesoblast shares to Angioblast stakeholders. This acquisition will enable Mesoblast to broaden its product pipeline across a wide range of clinical indications including cardiovascular, oncology, eye, and diabetes, in addition to its orthopedic range of products.

The issuance of new shares is anticipated to occur shortly, subject to formal documentation and closure of the transaction.

About Mesoblast Limited

Mesoblast Limited (ASX: MSB; ADR: MBLTY) is a world leader in commercialising biologic products for the broad field of regenerative medicine. Mesoblast has the worldwide exclusive rights for a series of patents and technologies developed over more than 10 years relating to the identification, extraction, culture and uses of adult Mesenchymal Precursor Cells (MPCs). www.mesoblast.com

For further information, please contact:

Julie Meldrum
Corporate Communications Director
T: + 61 (03) 9639 6036
E: julie.meldrum@mesoblast.com